To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on ...

Shire is to acquire rare disease company ViroPharma for $4.2 billion in a strategic move to boost its orphan drug portfolio. ViroPharma is a high growth, rare disease biopharma company ...

Cost savings have resulted in profitability gains despite mixed divisional performance ...